Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart observational study in adult atopic dermatitis involving special sites
ChiCTR2600121266Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guilin Medical University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of stapokibart in atopic dermatitis (AD), sponsored by The First Affiliated Hospital of Guilin Medical University. Primary endpoint: EASI 75 response rate at week 16. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2600121266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121266.